Of the 300 patients in the PARCER trial, 93 faced grades ≥2 adverse events (3D-CRT = 59, IG-IMRT = 34). Patients in the 3D-CRT and IG-IMRT arms spent an average of 2.39 years and 1.96 years in ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--HyperLight, creator of the TFLN Chiplet™ platform, today announced the launch of its groundbreaking 110 GHz Low Vπ Intensity Modulator, featuring industry-standard ...
Researchers at the Institute for Molecular Science (NINS, Japan) and SOKENDAI have demonstrated a more than 2000% voltage-induced enhancement of near-field nonlinear optical responses. To achieve this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results